Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New therapeutic approaches in sepsis: a critical review.

× No keyword cloud information.

15 in total

1. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.

Authors: R C Bone; C J Fisher; T P Clemmer; G J Slotman; C A Metz; R A Balk
Journal: N Engl J Med Date: 1987-09-10 Impact factor: 91.245

2. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid.

Authors: J D Baumgartner; M P Glauser; J A McCutchan; E J Ziegler; G van Melle; M R Klauber; M Vogt; E Muehlen; R Luethy; R Chiolero
Journal: Lancet Date: 1985-07-13 Impact factor: 79.321

3. Why have new effective therapies for sepsis not been developed?

Authors: L A Eidelman; C L Sprung
Journal: Crit Care Med Date: 1994-08 Impact factor: 7.598

4. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

Authors: R V McCloskey; R C Straube; C Sanders; S M Smith; C R Smith
Journal: Ann Intern Med Date: 1994-07-01 Impact factor: 25.391

5. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

Authors: C J Fisher; J F Dhainaut; S M Opal; J P Pribble; R A Balk; G J Slotman; T J Iberti; E C Rackow; M J Shapiro; R L Greenman
Journal: JAMA Date: 1994-06-15 Impact factor: 56.272

6. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial.

Authors: T Calandra; M P Glauser; J Schellekens; J Verhoef
Journal: J Infect Dis Date: 1988-08 Impact factor: 5.226

7. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis.

Authors:
Journal: N Engl J Med Date: 1987-09-10 Impact factor: 91.245

8. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies.

Authors: N N Teng; H S Kaplan; J M Hebert; C Moore; H Douglas; A Wunderlich; A I Braude
Journal: Proc Natl Acad Sci U S A Date: 1985-03 Impact factor: 11.205

9. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.

Authors: C J Fisher; G J Slotman; S M Opal; J P Pribble; R C Bone; G Emmanuel; D Ng; D C Bloedow; M A Catalano
Journal: Crit Care Med Date: 1994-01 Impact factor: 7.598

10. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels.

Authors: C H Wortel; M A von der Möhlen; S J van Deventer; C L Sprung; M Jastremski; M J Lubbers; C R Smith; I E Allen; J W ten Cate
Journal: J Infect Dis Date: 1992-12 Impact factor: 5.226

4 in total

Review 1. [Microcirculation and hemostasis in inflammatory processes. Modulation by administration of physiologic protease inhibitors as a therapeutic approach].

Authors: B Leithäuser; F R Matthias
Journal: Med Klin (Munich) Date: 1997-07-15

2. Effects of olprinone on hepatosplanchnic circulation and mitochondrial oxidation in a porcine model of endotoxemia.

Authors: Tamotsu Kuniyoshi; Yasuyuki Kakihana; Sumikazu Isowaki; Etsuro Nagata; Kazumi Tobo; Tatsuya Kaminosono; Tetsuaki Hashiguchi; Masamichi Tahara; Hirokazu Kawamae; Naoko Okayama; Yuichi Kanmura
Journal: J Anesth Date: 2005 Impact factor: 2.078

Review 3. Sepsis: clinical dilemmas.

Authors: M J Murray
Journal: Yale J Biol Med Date: 1998 Nov-Dec

4. Heat shock protein gene expression and survival in critical illness.

Authors: J Villar
Journal: Crit Care Date: 2000-01-24 Impact factor: 9.097

4 in total